682 results about "Arachidonic acid" patented technology

Engineered strains of the oleaginous yeast Yarrowia lipolytica capable of producing greater than 10% arachidonic acid (ARA, an ω-6 polyunsaturated fatty acid) in the total oil fraction are described. These strains comprise various chimeric genes expressing heterologous desaturases, elongases and acyltransferases, and optionally comprise various native desaturase and acyltransferase knockouts to enable synthesis and high accumulation of ARA. Production host cells are claimed, as are methods for producing ARA within said host cells.

The present inventions relate to therapeutic compositions comprising, and methods utilizing, arachidonic acid derivatives and analogs for treatment of patients demonstrating symptoms of pathological conditions. Specifically, the inventions relate to therapeutic compositions for activating transient receptor potential vanilloid-1 channels (TRPV1). Additionally, therapeutic compositions are provided for increasing TRPV1-type responses. These pathological conditions include, but are limited to, hypertension, in particular salt induced hypertension, and cardiovascular complications, including myocardial infarction, kidney dysfunction, diabetes, and inflammation. Further, the inventions relate to drug screening methods for providing additional therapeutic compounds.

Synthetic lipid composition in which the content and the distribution of the fatty acids are similar to those of human milk fat, containing less than 2% by weight of free fatty acids, in which palmitic acid is predominantly at the 2-position of the triacylglycerols and the arachidonic and docosahexaenoic acids are distributed between the 1-, 2- and 3-positions and in particular predominantly at the 2-position of the triacylglycerols.

A nutrition bar comprising about 10% wt or more of soy and/or rice protein, at least one transition metal or transition metal compound, and about 2% wt or more of a humectant, and wherein the at least one transition metal or transition metal compound is in a substantially water insoluble form at 20° C. or the nutrition bar has an Aw of 0.45 or less or about 1% wt or more of the soy and/or rice protein is in the form of nuggets and the humectant is selected from polyols. The bars have elevated levels of soy and/or rice protein, yet do not suffer unacceptable from a deterioration in taste or other organoleptic properties over time. In other aspects, a nutrition bar or other food which incorporates pro-oxidants and/or polyunsaturated fatty acids or their sources in encapsulated form, especially as microcapsules. The pro-oxidants may be metal salts such as copper, manganese, iron and/or zinc salts. Sources of omega-3 fatty acids include fish oil. Processes for preparing the polyunsaturated fatty acid capsules are also disclosed. The polyunsaturated fatty acid capsules/microcapsules are prepared by forming an emulsion of the unsaturated fatty acid with a carrier, spray drying the emulsion to form a powder and encapsulating powder, especially with a fluid bed. The invention is especially useful for encapsulating polyunsaturated fatty acids, or oil sources thereof, most preferably omega-3 and omega-6 fatty acids, such as arachidonic acid, docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), lineoleic acid, linolenic acid (alpha linolenic acid), and gamma-linolenic acids, fish oil, and oil sources of C18:2 and C18:3 fatty acids such as canola oil, soybean oil or blends thereof.

The invention relates to an anti-inflaming infant formula milk powder and a preparation process thereof. The anti-inflaming infant formula milk powder comprises the following components in percentage by weight: 22%-50% of lactose, 10%-20% of goat milk whey protein concentrate, 9.8%-20% of structural grease 1,3-dioleoyl 2-palmitoyl triglyceride, 10%-13.5% of non-fat goat milk powder, 8%-10% of vegetable oil, 2%-8% of beta-casein, 0.8%-1.6% of fructooligosaccharides, 0.5%-1.5% of mineral premix, 0.3%-1% of galactooligosaccharide, 0.2%-1% of immunoglobulin G, 0.2%-0.5% of lactulose, 0.10%-0.45% of arachidonic acid, 0.1%-0.6% of docosahexaenoic acid, 0.06%-0.12% of vitamin premix, 0.04%-0.06% of lactoferrin, and 0.01%-0.06% of nucleotide. The invention also includes the preparation process ofthe infant formula milk powder. The nutrition constituents and the functions of the infant formula milk powder are close to those of breast milk, the infant formula milk powder is easy to assimilate,and infants do not get inflamed after eating the milk powder.

The subject invention relates to the identification of several genes involved in the elongation of polyunsaturated acids (i.e., "elongases") and to uses thereof. At least two of these genes are also involved in the elongation of monounsaturated fatty acids. In particular, elongase is utilized in the conversion of gamma linolenic acid (GLA) to dihomogamma linolenic acid (DGLA) and in the conversion of AA to adrenic acid (ADA), or eicosapentaenoic acid (EPA) to omega3-docosapentaenoic acid (DPA). DGLA may be utilized in the production of polyunsaturated fatty acids, such as arachidonic acid (AA), docosahexaenoic acid (DHA), EPA, adrenic acid, omega6-docosapentaenoic acid or omega3-docosapentaenoic acid which may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

A method of treating a neurological disorder comprises administering to a person affected from such a disorder a microbial oil comprising DHA, a microbial oil comprising ARA or a combination of DHA and ARA oils in an amount sufficient to elevate the levels of circulating DHA and/or ARA in the person's blood to at least normal levels.

A Δ5 fatty acid desaturase gene, a Δ6 fatty acid desaturase gene, and a Δ6 fatty-acid-chain elongase gene are isolated from a single species of Marchantiales. By introducing these genes into higher plants, transformed plants which can produce arachidonic acid and eicosapentaenoic acid (EPA) are obtained.

The invention discloses a formula milk powder for promoting the absorption of fatty acid and calcium and a preparation method thereof. Raw cow milk, lactose, 1,3-Dioleoyl 2-palmitoyl triglyceride and demineralized whey powder as main materials are added with concentrated whey albumen powder, Alpha-lactalbumin powder, oligosaccharide, walnut oil, casein phosphopeptide, docosahexaenoic acid, arachidonic acid, nucleotide, lutein, inositol, carnitine and the like as well as vitamins, mineral substances and other nutrients needed for strengthening infants, and fat humanization, protein humanization and carbohydrate humanization are realized. The powdery product is produced by the processes of blending, homogenization, concentration, spray-drying, packaging and the like. According to the physiological characteristics and nutritional demand of the infants, the invention reinforces the calcium, the 1,3-Dioleoyl 2-palmitoyl triglyceride, other nutrient ingredients and the like, and aiming at the oversea clinical test conclusion of the 1,3-Dioleoyl 2-palmitoyl triglyceride, the final test conclusion of comparison with breast milk and infant formula milk powder sold on the market in the process of a clinical feeding test is that the feeding result of the designed formula approximates the feeding result of the breast milk and is better than the feeding result of an infant formula milk powder group sold on the market.

The invention relates to a method for the production of arachidonic acid in transgenic organisms, especially in transgenic plants and yeasts. The invention also relates to DNA sequences coding for a protein with enzymatic activity of a Δ5-desaturase from Phytophthera megasperma. The invention further relates to transgenic plants and plant cell and transgenic yeasts containing a nucleic acid molecule comprising a DNA sequence according to the present invention and having, on the basis thereof, an enhanced arachidonic acid synthesis in comparison with wild-type cells. The invention also relates to harvest products and propagating material of transgenic plants.

Oilseed plants which have been transformed to produce at least 8.0% arachidonic acid (ARA) as well as uses of oils and seeds obtained from such transformed plants in a variety of food and feed applications are described.

The present invention relates to a nutritional composition, in particular directed to children of 3-6 years, said nutritional composition comprising a protein source, a source of available carbohydrates, a lipid source, at least one probiotic microorganism, and prebiotics, wherein said lipid source comprises DHA (docosahexaenoic acid) and/or ARA (arachidonic acid). The nutritional composition improves cognitive performance, in particular memory, learning comprehension, alertness, attention, concentration, processing speed, conceptual thinking, abstract thinking, verbal abilities, language comprehension, psychomotor skills, curiosity, and confident interaction with the environment. Preferably, the composition comprises one, a combination of several or all selected of the group of DHA, ARA, LA, ALA, choline, iron, iodine and folic acid.

The invention relates to an infant nutrition immunity formula powdered milk and a production method thereof, wherein, the production method of the infant nutrition immunity formula powdered milk comprises the following steps: milk which is raw material, is preprocessed, the mixed solution of docosahexaenoic acid and arachidonic acid is prepared, ingredients are mixed, preheating, homogenizing and heating are carried out for sterilizing, decompression is carried out for concentrating, and spray-drying under negative pressure and low temperature and drying on a fluidized bed are carried out, then cooling, packing and inspecting are carried out. The infant nutrition immunity formula powdered milk manufactured by the method of the invention mainly comprises casein phosphoeptide, vitamin D3, lactoferrin, nucleotide, linoleic acid, linolenic acid, the docosahexaenoic acid, the arachidonic acid, fructo-oligosaccharide and galacto-oligosaccharide, which has the advantage of reasonable trophic structure and also ensures that various nutrient substance to be absorbed and deposited to the utmost extend, so as to promote the development of brain and nervous system, improve active immunity, improve intestinal tract micro-ecological environment and strengthen the absorption of calcium, iron and zinc as well as effectively maintain every active nutrient component during the production process.

The subject invention relates to the identification of a gene involved in the elongation of polyunsaturated fatty acids containing unsaturation at the carbon 9 position (i.e., “Δ9-elongase”) and to uses thereof. In particular, Δ9-elongase may be utilized, for example, in the conversion of linoleic acid (LA, 18:2n-6) to eicosadienoic acid (EDA, 20:2n-6). The production of dihomo-γ-linolenic acid (DGLA, 20:3n-6) from eicosadienoic acid (EDA, 20:2n-6), and arachidonic acid (AA, 20:4n-6) from dihomo-γ-linolenic acid (DGLA, 20:3n-6) is then catalyzed by Δ8-desaturase and Δ5-desaturase, respectively. AA or polyunsaturated fatty acids produced therefrom may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

An invention that adduces cogent evidence to establish that oxygenated dibenzo-α-pyrones (DBPs and their conjugates), the major bioactives of shilajit (Ayurvedic vitalizer), have their origin, at least partly, in EPA and DHA. Earlier research has shown that, in mammals, C-20 PUFAs are metabolized by oxygenases and other enzymes to produce short-lived prostaglandins, leukotrienes and thromboxanes that bind to specific G-protein-coupled receptors and signal cellular responses, e.g., inflammation, vasodilation, blood pressure, pain etc. But never before it was suggested/shown that C_20:5n-3 (and C_{22:6 n-3}) PUFAs, e.g., EPA (and DHA), are transformed into stable aromatic metabolites, DBPs, which elicit a large array of bioactivities in the producer organisms and also control the synthesis and metabolism of arachidonate-derived prostaglandins. The major beneficial effects attributed to EPA and DHA are now found to be largely contributed by DBPs and their aminoacyl conjugates and the dibenzo-α-pyrone-chromoproteins (DCPs). Because of the highly unstable nature of EPA and DHA, when administered, they are metabolized into a large array of uncontrolled products, several of which are systemically undesirable. By contrast, DBPs, because of their stability, perform the biological response modifier (BRM) functions in a directed and sustained way. Many of the biological effects of DBPs described in this invention, were earlier attributed to EPA and DHA,—the precursors of DBPs.

The present disclosure provides formulations and methods for delivering water-soluble and lipid-soluble nutrients for preventing or correcting nutrient deficiencies to subjects requiring small-volume nutritional support, such as preterm infants. The formulations may comprise an emulsion of docosahexaenoic acid (DHA) stabilized by a protein emulsifier, such as α-lactalbumin, and may further comprise other valuable nutrients, such as arachidonic acid (ARA), arginine, glutamine, arginyl-glutamine dipeptide and/or alanyl-glutamine dipeptide. The formulation is useful, for example, for correcting nutritional deficiencies by increasing a subject's intake of nutrients such as ω-3 or ω-6 long-chain polyunsaturated acids, proteins, peptides, vitamins, minerals, other fatty acids, and/or essential amino acids. The nutritional formulation is suitable for enteral delivery and small-volume delivery via nasogastric tube, intragastric feeding, transpyloric administration and/or any other means of administration that result in the introduction of the nutritional formulation into the digestive tract of a subject.

The invention discloses a separation method of silkworm pupa oil polyunsaturated fatty acid by gradient freezing crystallization, comprising the following steps of preprocessing silkworm pupas, extracting silkworm pupa oil with ultrasonic waves, preparing silkworm pupa oil mixed fatty acid, preparing a urea ethanol solution, and conducting urea inclusion treatment and then gradient freezing crystallization. Compared with the traditional separation methods of the silkworm pupa oil polyunsaturated fatty acid, the problem of fatty acid oxidation caused by overhigh temperature can be avoided because the whole operation process is conducted under low temperature all along. The silkworm pupa oil polyunsaturated fatty acid prepared by the invention contains 96.5% of polyunsaturated fatty acid (including 4.2% of linoleic acid, 91.3% of alpha-linoleic acid, and 1.0% of arachidonic acid), and can be served as principal components of relative drugs or health food. The invention has the advantages of simple processing step, high product yield, excellent quality, high purity of the polyunsaturated fatty acid and the like, and can be used for preparing the polyunsaturated fatty acid from silkworm pupa oil.

The invention discloses infant formula goat milk powder added with structural grease and a preparation method thereof. The infant formula goat milk powder is prepared from the following components: 20 to 40 percent of lactose, 16 to 22 percent of edible vegetable oil, 3.2 to 9.6 percent of structural grease (1,3-dioleic acid and 2-palmitic acid triglyceride), 16 to 22 percent of concentrated goatwhey protein, 11 to 15 percent of degreased goat milk powder, 2 to 6 percent of glucose syrup solid, 1.0 to 1.5 percent of fructooligosaccharide, 0.5 to 1.0 percent of galactooligosaccharide, 0.15 to0.50 percent of arachidonic acid, 0.12 to 0.48 percent of docosahexaenoic acid, 0.6 to 1.2 percent of mineral premix, 0.08 to 0.12 percent of vitamin premix, and 0.01 to 0.05 percent of nucleotide. The invention also discloses the preparation method of the infant formula goat milk powder. According to the infant formula goat milk powder, the goat smell is effectively eliminated, growth and development of infants are promoted, absorption and utilization rate of calcium are improved, and bone toughness of the infants is promoted.

The invention discloses a method for transforming fatty acid ethyl ester into glyceride, which comprises the following steps of: mixing the fatty acid ethyl ester and glycerol in a material tank; making the material pass through a glycerol separator by using a pump to separate free glycerin; then putting the material in a reactor in which immobilized lipase is filled; and making the material passthrough a packed tower to remove ethanol; making the material finally flow back to the material tank for performing 6 to 300h circular reaction; then carrying out molecular distillation on the reaction product to remove the unconverted reactant so as to obtain glyceride products. The method can improve the stability and bioavailability of the products, and has high application value for transforming functional fatty acids such as ethyl ester fish oil, algae oil, conjugated linoleic acid, arachidonic acid and the like into glyceride products.

This invention relates to the administration of arachidonic acid or docosahexaenoic acid or precursors thereof to children or pregnant women for the treatment or prevention of dyspraxia.

The invention provides an infant milk powder with adjusted structure of aliphatic acid, which comprises the following raw materials (by weight portion in tons): dry matter of fresh milk 276, desalinized whey powder 450, structured fatty oil 105, lactose 50, fructooligosaccharide 20, alpha-lactalbumin 10, docosahexaenoic acid 5, arachidonic acid 6, nucleic acid 0. 42, taurine 0. 45, choline 0. 42, L-carnitine 0. 06, beta-carotene 0. 012, composite vitamin 2. 5, composite microelement 3. 5 and balancing refined vegetable oil.

The invention relates to a plant seed oil, comprising arachidonic acid comprising approximately 7 to approximately 26 percent by weight of the total fatty acid content, the ratio of the percentages by weight of arachidonic acid to gamma-linolenic acid being approximately 1:1 to approximately 5:1 and the ratio of the percentages by weight of arachidonic acid to dihomo-gamma-linolenic acid being approximately 1:1 to approximately 5:1. The invention additionally relates to processes for the production of this plant seed oil and formulations and uses of the plant seed oil. In particular, the invention also makes available foodstuffs and baby food that contain the plant seed oil mentioned.